Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting ; day:1 ; month:8 ; year:2020 ; pages:1-8
Breast cancer research and treatment ; (1.8.2020), 1-8
- Urheber
-
Joona, Therse Björkin
Digkas, Evangelos
Wennstig, Anna-Karin
Nyström, Karin
Nearchou, Andreas
Nilsson, Cecilia
Pauksens, Karlis
Valachis, Antonis
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-020-05815-y
- URN
-
urn:nbn:de:101:1-2020092712120947392166
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Joona, Therse Björkin
- Digkas, Evangelos
- Wennstig, Anna-Karin
- Nyström, Karin
- Nearchou, Andreas
- Nilsson, Cecilia
- Pauksens, Karlis
- Valachis, Antonis
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mucosal Vaccination for Influenza Protection Enhanced by Catalytic Immune‐Adjuvant
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
The antibody response in the bovine mammary gland is influenced by the adjuvant and the site of subcutaneous vaccination
Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
Development of a subcutaneous malaria whole-parasite vaccination
Influenza vaccination in pediatric age
Psychological determinants of influenza vaccination
Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
Mucosal Vaccination for Influenza Protection Enhanced by Catalytic Immune‐Adjuvant
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
The antibody response in the bovine mammary gland is influenced by the adjuvant and the site of subcutaneous vaccination
Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
Development of a subcutaneous malaria whole-parasite vaccination
Influenza vaccination in pediatric age
Psychological determinants of influenza vaccination
Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
Mucosal Vaccination for Influenza Protection Enhanced by Catalytic Immune‐Adjuvant
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
The antibody response in the bovine mammary gland is influenced by the adjuvant and the site of subcutaneous vaccination
Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
Development of a subcutaneous malaria whole-parasite vaccination
Influenza vaccination in pediatric age
Psychological determinants of influenza vaccination